In 2025, Dupixent (dupilumab), developed by Sanofi and Regeneron, continues to solidify its position as a leading treatment for various inflammatory diseases. Recent FDA approvals and impressive sales figures underscore its growing significance in the…
Calcort, the trade name for deflazacort in the United Kingdom, has been a cornerstone in the management of Duchenne Muscular Dystrophy (DMD) for decades. As a glucocorticoid with anti-inflammatory and immunosuppressive properties, deflazacort offers therapeutic…
Cystadane® (betaine anhydrous for oral solution) has long been a cornerstone in the treatment of homocystinuria, a rare genetic disorder characterized by elevated levels of homocysteine in the blood and urine. Approved by the U.S.…
In 2025, Cinryze (C1 inhibitor [human]), a plasma-derived therapy developed by Shire (now part of Takeda Pharmaceuticals), continues to play a pivotal role in the management of hereditary angioedema (HAE). As the first FDA-approved treatment…
Xolremdi(mavorixafor) is an innovative pharmaceutical compound that has gained significant attention in the medical and biotech industries. As a potential game-changer in targeted therapies, Xolremdi is being studied for its unique mechanism of action and…
Ojemda(tovorafenib) is an innovative precision medicine designed to combat specific types of cancer by targeting genetic mutations. As a next-generation kinase inhibitor, it represents a significant advancement in oncology, offering hope for patients with limited…
Anktiva(nogapendekin alfa inbakicept-pmln) is a cutting-edge therapeutic agent that has garnered significant attention in the medical and biotech communities. Understanding Anktiva’s mechanisms, applications, and benefits is crucial for healthcare professionals, researchers, and others exploring new…
Zevtera® (ceftobiprole medocaril sodium) is a fifth-generation cephalosporin antibiotic developed by Basilea Pharmaceutica. Approved by the U.S. FDA in April 2024, Zevtera offers a potent treatment option against a range of serious bacterial infections, including…
🫁 What Is Sotatercept-csrk? Winrevair™ (sotatercept-csrk) is a pioneering biologic therapy developed by Merck, approved by the FDA in March 2024 for the treatment of adults with pulmonary arterial hypertension (PAH), classified as World Health…
Antibiotic resistance poses a significant challenge to modern medicine, rendering many traditional antibiotics less effective against certain bacterial infections. In response, new treatments like Exblifep have been developed to address resistant pathogens. This article delves…
Caffeic Acid tablets, as a drug with the functions of hemostasis and leukocyte elevation, have demonstrated remarkable efficacy in clinical application in several departments in recent years. Wide Clinical Application According to Tencent News, Caffeic…
Tryvio (aprocitentan) is a novel antihypertensive medication developed by Idorsia Pharmaceuticals. Approved by the U.S. Food and Drug Administration (FDA) in March 2024, it offers a new therapeutic option for patients with resistant hypertension—those whose…
